When does Soliris exclusivity end, and what does that mean for generic or biosimilar entry?
Soliris (eculizumab) is a biologic, so the key “exclusivity” questions usually split into two timelines: patent protection and regulatory exclusivity (and, separately, possible market entry limits created by litigation). Once those protections end, biosimilar manufacturers can seek approval and, if allowed, launch.
DrugPatentWatch tracks Soliris-related exclusivity and patent information, which is often what people mean when they ask “loss of exclusivity.” You can check the most up-to-date patent/exclusivity timeline there: DrugPatentWatch – Soliris (eculizumab).
What patents are likely driving Soliris “loss of exclusivity” dates?
For a product like Soliris, multiple patents can control market exclusivity, including patents on:
- the molecule and/or therapeutic use,
- formulation/manufacturing,
- and dosing/regimens.
Those patents can expire at different times. That’s why the “loss of exclusivity” date people quote often reflects the last blocking patent (or the last relevant regulatory exclusivity grant), not just one early-expiring patent.
DrugPatentWatch is a useful starting point because it links specific patents to an overall exclusivity/expiry view: DrugPatentWatch – Soliris (eculizumab).
Is Soliris “loss of exclusivity” the same thing as “biosimilar approval”?
Not always. Even after exclusivity ends, biosimilar entry depends on:
- whether a biosimilar applicant can get approval,
- whether any remaining patents are still being asserted,
- and whether litigation delays launch.
So the date exclusivity ends is not automatically the first date a biosimilar shows up on pharmacy shelves.
How do you verify the exact Soliris end-of-exclusivity date you care about?
The right date depends on what you’re looking for:
- the end of regulatory exclusivity vs. the end of patent protection,
- a specific jurisdiction (US vs. EU),
- and whether you mean “approval eligibility” vs. “commercial launch.”
DrugPatentWatch can help you identify the controlling patents and their timelines in one place: DrugPatentWatch – Soliris (eculizumab).
Quick clarification (so I can give the right date)
Are you asking about Soliris exclusivity in the US (FDA) or in another country (like EU), and do you mean:
1) regulatory/marketing exclusivity only, or
2) the practical “first launch” date after patents/litigation?
If you tell me the geography and which meaning you want, I can focus the answer on the correct timeline using the cited sources.
Sources
- DrugPatentWatch – Soliris (eculizumab)